Penny Stocks – If You Don’t Bullish on Onconova Therapeutics, Inc. (NASDAQ:ONTX) Now, You’ll Regret Your Decision Later

The trading price of Onconova Therapeutics, Inc. (NASDAQ:ONTX) closed lower on Friday, Feb 19, closing at $1.76, -7.1% lower than its previous close.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Traders who pay close attention to intraday price movement should know that it fluctuated between $1.5000 and $1.7000. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 2.37. In examining the 52-week price action we see that the stock hit a 52-week high of $1.93 and a 52-week low of $0.19. Over the past month, the stock has gained 117.83% in value.

Onconova Therapeutics, Inc., whose market valuation is $368.81 Million at the time of this writing, is expected to release its quarterly earnings report in Apr 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.03 per share this quarter, however they have predicted annual earnings per share of -$0.14 for 2021 and -$0.14 for 2022. It means analysts are expecting annual earnings per share growth of -0.91% this year and 0% next year.

Analysts have forecast the company to bring in revenue of $40Million for the quarter, with the likely lows of $30Million and highs of $50Million. The average estimate suggests sales will likely down by -20% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $210Million. The company’s revenue is forecast to drop by -90.4% over what it did in 2020.

On the technical side, indicators suggest ONTX has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 50% Buy.

Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned ONTX a recommendation rating is 4. Out of them, 3 rate it a Hold, while 1 recommend Buy, whereas none assign an Outperform rating. None analyst(s) have tagged Onconova Therapeutics, Inc. (ONTX) as Underperform, while not any of them advise Sell. Analysts have rated the stock Hold, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.

If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. A quick review shows that ONTX’s price is currently 71.34% off the SMA20 and 137.05% off the SMA50. The RSI metric on the 14-day chart is currently showing 77.73, and weekly volatility stands at 20.51%. When measured over the past 30 days, the indicator reaches 16.08%. Onconova Therapeutics, Inc. (NASDAQ:ONTX)’s beta value is currently sitting at 2.37, while the Average True Range indicator is currently displaying 0.2. With analysts defining $0.46-$0.46 as the low and high price targets, we arrive at a consensus price target of $0.46 for the trailing 12-month period. The current price is about -71.78% off the estimated low and -71.78% off the forecast high, based on this estimate. Investors will be thrilled if ONTX’s share price rises to $0.46, which is the median consensus price. At that level, ONTX’s share price would be -71.78% above current price.

To see how Onconova Therapeutics, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: ONTX stock’s performance was -7.1% in the latest trading, and +200.33% in the past year, while Zoetis Inc Cl A (ZTS) has traded -4.73% on the day and positioned +11.46% higher than it was a year ago. Another comparable company Takeda Pharmaceutical CO Ltd (TAK) saw its stock close 1.14% higher in the most recent trading session but was down -4.85% in a year. Furthermore, Catalent Inc (CTLT) showed a decline of -7.1% on the day while its price kept rising at 200.33% over the past year. Onconova Therapeutics, Inc. has a P/E ratio of 0, compared to Zoetis Inc Cl A’s 46.74 and Takeda Pharmaceutical CO Ltd’s 21.77. Also in last trading session, the S&P 500 Index has soared -0.19%, while the Dow Jones Industrial also saw a negative seesion, down 0% on the day.

An evaluation of the daily trading volume of Onconova Therapeutics, Inc. (NASDAQ:ONTX) indicates that the 3-month average is 52.34 Million. However, this figure has declined over the past 10 days to an average of 173.09 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Currently, records show that 236.51 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 0.56% of outstanding shares, whereas institutions hold 11.21%. The stats also highlight that short interest as of January 28, 2021, stood at 12.67 Million shares, resulting in a short ratio of 0.31 at that time. From this, we can conclude that short interest is 6.13% of the company’s total outstanding shares. It is noteworthy that short shares in January were down slightly from the previous month’s figure, which was 14.21 Million. However, since the stock’s price has seen +251.01% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.